Verrica Pharmaceuticals Inc [VRCA] stock prices are up 8.63% to $1.51 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VRCA shares have gain 17.97% over the last week, with a monthly amount drifted -14.69%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Verrica Pharmaceuticals Inc [NASDAQ: VRCA] stock has seen the most recent analyst activity on July 25, 2023, when Needham upgraded its rating to a Buy but kept the price target unchanged to $10 for it. Previously, Jefferies started tracking the stock with Buy rating on March 22, 2023, and set its price target to $10. On February 13, 2023, upgrade upgraded it’s rating to Outperform and revised its price target to $11 on the stock. RBC Capital Mkts downgraded its rating to a Sector Perform and decreased its price target to $4 on May 25, 2022. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $19 as its price target on May 14, 2021. H.C. Wainwright reiterated a Buy rating for this stock on December 24, 2020, and upped its price target to $21. In a note dated July 15, 2020, BofA Securities downgraded an Neutral rating on this stock.
The stock price of Verrica Pharmaceuticals Inc [VRCA] has been fluctuating between $1.04 and $11.41 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Verrica Pharmaceuticals Inc [NASDAQ: VRCA] shares were valued at $1.51 at the most recent close of the market. An investor can expect a potential return of 694.7% based on the average VRCA price forecast.
Analyzing the VRCA fundamentals
The Verrica Pharmaceuticals Inc [NASDAQ:VRCA] reported sales of 13.91M for trailing twelve months, representing a surge of 2744.51%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -5.63%, Pretax Profit Margin comes in at -6.25%, and Net Profit Margin reading is -6.25%. To continue investigating profitability, this company’s Return on Assets is posted at -1.67, Equity is -6.92 and Total Capital is -2.45. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -3.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3733 points at the first support level, and at 1.2367 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6533, and for the 2nd resistance point, it is at 1.7967.
Ratios To Look Out For
It’s worth pointing out that Verrica Pharmaceuticals Inc [NASDAQ:VRCA]’s Current Ratio is 2.36. Also, the Quick Ratio is 2.23, while the Cash Ratio stands at 1.59. Considering the valuation of this stock, the price to sales ratio is 4.63.
Transactions by insiders
Recent insider trading involved Hayes Christopher G., CHIEF LEGAL OFFICER, that happened on Aug 26 ’24 when 26183.0 shares were sold. CHIEF LEGAL OFFICER, Hayes Christopher G. completed a deal on Aug 27 ’24 to sell 9530.0 shares. Meanwhile, Chief Medical Officer Goldenberg Gary sold 9888.0 shares on Aug 26 ’24.
